Improvement in patient-reported outcomes after rituximab in rheumatoid arthritis patients: An open-label assessment of 175 patients

ObjectivePatient-reported outcomes (PROs) reflect treatment efficacy from the patients’ perspective. The objective was to assess PROs improvement with rituximab in rheumatoid arthritis.MethodsPatients with long-standing rheumatoid arthritis received rituximab 1000 mg twice at 2 weeks interval, and were assessed over 6 months. PROs including physical PROs (pain, functional assessment, physical quality of life) and mental or mixed aspects (fatigue, sleep and mental quality of life) were assessed. Standardized response means were calculated. Early improvement in PROs was used to predict EULAR response at 6 months.ResultsFor the 175 patients (mean age 54.6 ± 10.6 years, mean disease duration 12.9 ± 9.3 years), the plateau of efficacy of rituximab on PROs was reached at week 12, and the effect was more prominent on physical PROs (e.g., pain standardized response means −0.75 [95% confidence interval −0.91; −0.60]), than on sleep (−0.43; [−0.56; −0.29]). It was not possible to accurately predict 6-month EULAR response by early improvement in PROs.ConclusionRituximab was effective on PROs with an early effect. PROs reflecting physical aspects were more modulated by this biologic than other PROs (fatigue, sleep or mental quality of life). Links between sleep difficulties, fatigue and RA should be further studied.